ArticleBlood2026
Integrin αvβ8-mediated TGF-β1 activation regulates the sustained response in immune thrombocytopenia after TPO-RA withdrawal.
Article in Blood, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Single-Cell Transcriptomic Profiling Identifies B Cell-Intrinsic Dysregulation of Sphingolipid Biosynthesis and Could Be Improved by Inhibiting UGCG in Primary Immune Thrombocytopenia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Artificial intelligence prediction of therapy response in newly diagnosed adult severe primary immune thrombocytopenia.Research and practice in thrombosis and haemostasis · 2026Article
- Osteoblast-derived osteomodulin restrains osteoclastogenesis via ITGB8/RRM2-mediated reduction of mitochondrial respiration and mitochondrial ATP production.Experimental & molecular medicine · 2026Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractOnly 30% to 50% of patients with immune thrombocytopenia (ITP) exhibit a sustained response upon thrombopoietin receptor agonists (TPO-RA) withdrawal, underscoring the necessity for mechanistic elucidation. We enrolled 49 patients treated with TPO-RA for 4 months and performed a follow-up study for 3 months, classifying them into sustained responders (n = 21), and nonsustained responders (n = 28). Compared with total transforming growth factor β1 (TGF-β1) levels, activated TGF-β1 levels (3854 ± 4380 vs 943 ± 1500 pg/mL; P< .001) were significantly elevated in sustained responders, with integrin αvβ8 regulating TGF-β1 activation and restoring immune tolerance. We established a passive ITP model using platelet factor 4-TGF-β1 conditional knockout (CKO) mice, which exhibited a shorter duration of sustained response than wild-type (WT) mice. CKO mice demonstrated a reduced regulatory T-cell (Treg) population, an increased M1-to-M2 macrophage ratio, and more severe megakaryocyte destruction after anti-CD41 injection. Exogenous administration of αvβ8 (250 ng/kg) effectively activated TGF-β1 and prolonged remission after TPO discontinuation in WT mice. Additionally, CD4+ T cells were transfected with lentiviral small interfering RNA or short hairpin RNA to modulate integrin β8 expression and these were injected into severe combined immunodeficiency mice undergoing an active model of ITP. Results showed that β8 overexpression increased Tregs and reduced megakaryocyte damage. Mechanistically, TPO-RA modulated αvβ8-mediated TGF-β1 activation through the activator protein 1family and Smad family member 2 signaling pathways. Furthermore, D-mannose combined with TPO prolonged the response in ITP mice by upregulating αvβ8 and activating TGF-β1. Overall, the integrin αvβ8-mediated activation of TGF-β1 pathway represents a promising therapeutic target for ITP, with substantial potential for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.